Shockwave Medical, Inc. SWAV recently announced that the researchers provided interim long-term follow-up results of up to three years, along with six-month data from the entire population of the ...
SANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...
SANTA CLARA, Calif. - Shockwave Medical , Inc. (NASDAQ: NASDAQ:SWAV) announced today that recent data from the REDUCER-I trial presented at the American College of Cardiology's 73rd Annual Scientific ...
Photo Credit: Adapted from Verheye S. The coronary sinus reducer. Presented at: TCT 2023. San Francisco, CA. An implantable coronary sinus reducer (CSR)—Shockwave Reducer (Shockwave Medical)—likely ...
(MENAFN- GlobeNewsWire - Nasdaq) Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina SANTA CLARA, Calif., April 08, 2024 (GLOBE ...